63 Result(s)
within
Victor L. Villemagne
-
Article
Intravenous Nicotine Reduces Cerebral Glucose Metabolism: A Preliminary Study
Nicotine is self-administered by smoking tobacco products, and enhances positive mood (at least in smokers). Since most drugs of abuse decrease regional cerebral metabolic rate(s) for glucose (rCMRglc) in huma...
-
Article
The ART of Loss: Aβ Imaging in the Evaluation of Alzheimer’s Disease and other Dementias
Molecular neuroimaging based on annihilation radiation tomographic (ART) techniques such as positron emission tomography (PET), in conjunction with related biomarkers in plasma and cerebrospinal fluid (CSF), a...
-
Article
Amyloid Imaging in Alzheimer’s Disease and Other Dementias
With the advent of new therapeutic strategies aimed at reducing β-amyloid (Aβ) burden in the brain to potentially prevent or delay functional and irreversible cognitive loss, there is increased interest in dev...
-
Protocol
Quantitative Approaches to Amyloid Imaging
Alzheimer’s disease (AD), an irreversible, progressive neurodegenerative disorder clinically characterized by memory loss and cognitive decline, is the leading cause of dementia in the elderly, leading invaria...
-
Chapter and Conference Paper
MR-Less Surface-Based Amyloid Estimation by Subject-Specific Atlas Selection and Bayesian Fusion
For clinical evaluation, assessing amyloid deposition with PiB-PET is desirable without requiring MR acquisition and associated fusion/segmentation techniques. A useful clinical tool is to estimate PiB-PET aga...
-
Protocol
Emission Imaging in Dementia
Dementia is typically associated with progressive impairments in memory and cognition that are beyond what is expected during the normal aging process; these impairments can also be accompanied by behavioral a...
-
Article
Open AccessAβ Imaging: feasible, pertinent, and vital to progress in Alzheimer’s disease
-
Article
Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease
Amyloid imaging with 18F-labelled radiotracers will allow widespread use of this technique, facilitating research, diagnosis and therapeutic development for Alzheimer’s disease (AD). The purpose of this analysis ...
-
Article
Open Access18F-florbetaben Aβ imaging in mild cognitive impairment
18F-florbetaben and positron emission tomography were used to examine the relationships between β-amyloid (Aβ) deposition, cognition, hippocampal volume, and white matter hyperintensities in mild cognitive impai....
-
Article
Oligomers, fact or artefact? SDS-PAGE induces dimerization of β-amyloid in human brain samples
The formation of low-order oligomers of β-amyloid (Aβ) within the brain is widely believed to be a central component of Alzheimer’s disease (AD) pathogenesis. However, despite advances in high-throughput and h...
-
Article
Open AccessIn vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106
The activation of microglia, in general, and the upregulation of the translocator protein (18 kDa) (TSPO) system, in particular, are key features of neuroinflammation, of which the in vivo visualization and quant...
-
Article
Open AccessAssessing THK523 selectivity for tau deposits in Alzheimer’s disease and non–Alzheimer’s disease tauopathies
The introduction of tau imaging agents such as 18F-THK523 offers new hope for the in vivo assessment of tau deposition in tauopathies such as Alzheimer’s disease (AD), where preliminary 18F-THK523-PET studies hav...
-
Article
In vivo evaluation of a novel tau imaging tracer for Alzheimer’s disease
Diagnosis of tauopathies such as Alzheimer’s disease (AD) still relies on post-mortem examination of the human brain. A non-invasive method of determining brain tau burden in vivo would allow a better understa...
-
Article
Do current therapeutic anti-Aβ antibodies for Alzheimer’s disease engage the target?
Reducing amyloid-β peptide (Aβ) burden at the pre-symptomatic stages of Alzheimer’s disease (AD) is currently the advocated clinical strategy for treating this disease. The most developed method for targeting ...
-
Article
Open AccessImago Mundi, Imago AD, Imago ADNI
Since the launch in 2003 of the Alzheimer’s Disease Neuroimaging Initiative (ADNI) in the USA, ever growing, similarly oriented consortia have been organized and assembled around the world. The various accompl...
-
Article
Anti-Aβ antibody target engagement: a response to Siemers et al.
-
Article
The landscape of ageing—insights from AD imaging markers
The knowledge of imaging and fluid biomarkers gained from longitudinal observational studies of Alzheimer disease has recently been translated to a cross-sectional study of randomly selected, cognitively unimp...
-
Chapter and Conference Paper
CapAIBL: Automated Reporting of Cortical PET Quantification Without Need of MRI on Brain Surface Using a Patch-Based Method
Molecular brain imaging using Positron Emission Tomography (PET) is a robust diagnostic tool for which several tracers labelled with either 11C or 18F are available. For visual inspection of the images, cortical ...
-
Article
Suspected non-Alzheimer disease pathophysiology — concept and controversy
Suspected non-Alzheimer disease pathophysiology (SNAP) is a biomarker-based concept that applies to individuals with normal levels of amyloid-β biomarkers in the brain, but in whom biomarkers of neurodegenerat...
-
Article
Innate phagocytosis by peripheral blood monocytes is altered in Alzheimer’s disease
Sporadic Alzheimer’s disease (AD) is characterised by the deposition and accumulation of specific protein aggregates. Failure of clearance could underlie this process, and recent genetic association studies po...
